Case Report

Plasma Therapy for Medication-Related Osteonecrosis of the Jaws- A Case Report

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of anti-bone resorption medications. Nowadays antiresorptive medications like bisphosphonate and monoclonal antibodies like denosumab that have been prescribed for bone disorders and metastatic cancer are becoming increasingly common. Although these medications are quite efficient at reducing bone resorption, they can develop osteomyelitis and jaw necrosis as a side effect. A 65-year-old woman was referred to the Oral Medicine Department of Semnan University of Medical Sciences with diffuse bilateral mandibular osteonecrosis, with a history of osteopetrosis and under-treatment of bisphosphonate. This complication started after tooth extraction and without any healing 5 years ago. After 3 sessions of plasma therapy, obvious improvement was seen. A proper medical history and a routine oral examination before treating with any invasive dental treatment are necessary to avoid any medication-related osteonecrosis of the jaw or mucosal abnormalities.

[1] Zornitza Stark and Ravi Savarirayan. Osteopetrosis. Orphanet J Rare Dis. Feb 2009, 20;4:5. [DOI: 10.1186/1750-1172-4-5. [PubMed]
[2] Robert Blank. Osteopetrosis. Medscape Reference. December 2014; [http://emedicine.medscape.com/article/123968-overview]
[3] Osteonecrosis. National Institutes of Arthritis and Musculoskeletal and Skin disease, Maryland, 2020 [https://www.niams.nih.gov/health-topics/osteonecrosis]
[4] Weinstein RS, Roberson PK, Manolagas SC (January 2009). "Giant osteoclast formation and long-term oral bisphosphonate therapy". N. Engl. J. Med. 360 (1): 53–62. [DoI: 10.1056/NEJMoa0802633. PMC 2866022. PMID 19118304]
[5] Ruggiero SL, Dobson TB, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medicationrelated Osteonecrosis of the Jaw 2014. J Oral Maxillofac Surg. 2014 ;72(10):1938-56. [DOI: 10.1016/j.joms.2014.04.031]
[6] Rolason V, Laverrière A, MasDonald LCI. Interventions for treating bisphosphonate-related osteonecrosis of the jaw [BRONJ. Cochrane Database Syst Rev. 2016, 26;2(2):CD008455]
[7] Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP,
Monkkonen J, et al. Cellular and molecular mechanisms of action of
bisphosphonates. Cancer. 2000; 88:2961–78. [PubMed] [Google
Scholar.]
[8] Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002; 32:94–124. [PubMed] [Google Scholar].
[9] Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005; 104:83–93. [PubMed] [Google Scholar]
[10] Seunghee C and Young-Seok P, Plasma in dentistry, Clin Plasma Med. 2014 July; 2(1): 4–10. [DOI:10.1016/j. cpme.2014.04.002]
Files
IssueVol 8 No 1 (2023): Janyary-February QRcode
SectionCase Report(s)
DOI https://doi.org/10.18502/crcp.v8i1.13088
Keywords
Osteonecrosis Bisphosphonate Osteopetrosis Plasma MRONJ

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Jalili Sadrabad M, Saberian E. Plasma Therapy for Medication-Related Osteonecrosis of the Jaws- A Case Report. CRCP. 2023;8(1):1-4.